^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
CTX131
i
Other names: CTX131, CTX-131, CTX 131
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
CRISPR Therap
Drug class:
CD70-targeted CAR-T immunotherapy
Related drugs:
5d
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=12, Completed, CRISPR Therapeutics | Recruiting --> Completed | N=290 --> 12 | Trial completion date: Nov 2030 --> Mar 2026 | Trial primary completion date: May 2030 --> Mar 2026
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
CTX131
4ms
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors (clinicaltrials.gov)
P1/2, N=19, Completed, CRISPR Therapeutics AG | Recruiting --> Completed | N=250 --> 19 | Trial completion date: May 2030 --> Sep 2025 | Trial primary completion date: Apr 2030 --> Sep 2025
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
CTX131
over1year
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. (PubMed, Lancet Oncol)
In patients with heavily pretreated T-cell lymphoma, CTX130 showed manageable safety and a promising objective response rate. This study shows that allogeneic, readily available CAR T cells can be safely given to patients with relapsed or refractory T-cell lymphoma. A next-generation CAR T-cell therapy containing additional potency gene edits (CTX131) is in clinical development.
P1 data • Journal • CAR T-Cell Therapy
|
CD70 (CD70 Molecule)
|
cyclophosphamide • fludarabine IV • CTX130 • CTX131
over1year
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=290, Recruiting, CRISPR Therapeutics | Not yet recruiting --> Recruiting
Enrollment open
|
CTX131
over1year
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=290, Not yet recruiting, CRISPR Therapeutics
New P1/2 trial
|
CTX131
2years
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma. (PubMed, Cancer Discov)
Finally, we report on a next-generation CAR T construct, CTX131, in which synergistic potency edits to CTX130 confer improved expansion and efficacy in preclinical studies. Although the role of CAR T cells is well established in hematologic malignancies, the clinical experience in solid tumors has been disappointing. This clinical trial demonstrates the first complete response in a patient with RCC, reinforcing the potential benefit of CAR T cells in the treatment of solid tumors.
Journal • CAR T-Cell Therapy • Metastases
|
CD70 (CD70 Molecule)
|
CTX130 • CTX131
Share via
